score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical trial			Copy Number	BRCA2	Deletion				0.0	0.0		Putatively Actionable	Olaparib	PARP inhibition	Targeted therapy	Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.	Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.	https://doi.org/10.1056/NEJMoa1506859													0				BRCA2 Deletion	1.0	PROS01448-1115244	PROS01448-1115244-Tumor-SM-5SGU6	
Putatively Actionable		Clinical evidence		Somatic Variant	AR	Missense	p.L702H	0.5806	31.0	0.0	0.0									Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	33.0	0.9394	1.0	AR p.L702H (Missense)		PROS01448-1115244	PROS01448-1115244-Tumor-SM-5SGU6	PROS01448-1115244-Normal-SM-6CAJP
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	COL1A1--KLK3			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				COL1A1--KLK3 Fusion	0.0	PROS01448-1115244		
Biologically Relevant				Copy Number	ZRSR2	Amplification				0.0	0.0																					0				ZRSR2 Amplification		PROS01448-1115244	PROS01448-1115244-Tumor-SM-5SGU6	
Biologically Relevant				Copy Number	BCOR	Amplification				0.0	0.0																					0				BCOR Amplification		PROS01448-1115244	PROS01448-1115244-Tumor-SM-5SGU6	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		PROS01448-1115244		
Biologically Relevant				Mutational Signature	COSMIC Signature 15	version 2	0.209																									0				COSMIC Signature (version 2) 15 (21%)		PROS01448-1115244		
